Drugs /
eftilagimod alpha
Overview
Clinical Trials
Eftilagimod alpha has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating eftilagimod alpha, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).
ER Expression, ER Positive, and PR Expression are the most frequent biomarker inclusion criteria for eftilagimod alpha clinical trials.
Breast adenocarcinoma, breast carcinoma, and head and neck squamous cell carcinoma are the most common diseases being investigated in eftilagimod alpha clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.